Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Sep 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Sep 2027
Next term end
6
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2039.
US 8,187,876
Expansion of Stem/Progenitor Cells by Inhibition of Enzymatic Reactions Catalyzed by the SIR2 Family of Enzymes
no later than Sep 19, 2027
US 11,730,771
Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation
Jan 5, 2039
US 11,746,325
Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation
Jan 5, 2039
20182024203020362039
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
4 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2029 · Medium confidence
Also notable
Ends Jan 2039 · High confidence
Also notable
Ends Feb 2039 · High confidence
Methods of Improving Stem Cell Homing and Engraftment
US 8,846,393
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2029.
Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation
US 11,746,325
The newest of the three, granted 2023. It anchors the portfolio to 2039, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
Expansion and Use of Expanded NK Cell Fractions
US 11,834,677
The newest of the three, granted 2023. It anchors the portfolio to 2039, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation (US 11,730,771) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation (US 11,746,325) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Enhancement of Natural Killer (NK) Cell Proliferation and Activity (US 9,175,266) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Expansion and Use of Expanded NK Cell Fractions (US 11,834,677) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Expansion and Use of Expanded NK Cell Fractions | 1 in force | to Feb 2039 |
| Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation (2019) | 1 in force | to Jan 2039 |
| Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation (2019) | 1 in force | to Jan 2039 |
| Methods of Improving Stem Cell Homing and Engraftment | 1 in force | to Feb 2029 |
| Expansion of Stem/Progenitor Cells by Inhibition of Enzymatic Reactions Catalyzed by the SIR2 Family of Enzymes | 1 in force | to Sep 2027 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,187,876 | Expansion of Stem/Progenitor Cells by Inhibition of Enzymatic Reactions Catalyzed by the SIR2 Family of Enzymes In force · Medium confidence | In force | Medium confidence | |
| US 8,846,393 | Methods of Improving Stem Cell Homing and Engraftment In force · Medium confidence | In force | Medium confidence | |
| US 9,175,266 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity In force · High confidence | In force | High confidence | |
| US 11,730,771 | Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation In force · High confidence | In force | High confidence | |
| US 11,746,325 | Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation In force · High confidence | In force | High confidence | |
| US 11,834,677 | Expansion and Use of Expanded NK Cell Fractions In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 11 patents ended · 4 applications pending · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.